Publication

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.

Abstract
The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.
Citation
Döhner H, DiNardo CD, Wei AH, Löwenberg B, Appelbaum F, Craddock C, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele GJ, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024 Aug 12:blood.2024025409.
Journal / Source Title
Blood
DOI
10.1182/blood.2024025409
PMID
39133932
Publisher
Elsevier
Publisher’s URL
https://www.sciencedirect.com/journal/blood
Publisher’s statement
Note / Copyright